← Back to Search
Lung Cancer And Other Thoracic Malignancies
M. Harkenrider, S. R. Silva, R. Decker
Published 2017 · Medicine
Download PDFAnalyze on Scholarcy
Lung cancer is the deadliest malignancy in the United States, and much research has been dedicated over the last many decades to improve patient outcomes. Smoking cessation education, lung cancer screening, improved diagnostic and functional imaging, improved surgical and radiation techniques, multimodality therapy, and targeted biologic and immunologic therapy have all lead to earlier detection of lung cancer and improved treatment resulting in improvements in overall survival. There are still many controversies that exist within each of these many aspects in the diagnosis and treatment of lung cancer. This chapter is dedicated to the controversies that exist in the management and treatment of all aspects of lung cancer with additional discussion of the controversies regarding thymoma and malignant pleural mesothelioma.
This paper references
Radiation therapy in the treatment of superior vena caval obstruction
D. Davenport (1978)
Re-evaluating the role of palliative radiotherapy in malignant pleural mesothelioma.
P. Jenkins (2011)
Hemithoracic intensity modulated radiation therapy after pleurectomy/decortication for malignant pleural mesothelioma: toxicity, patterns of failure, and a matched survival analysis.
W. W. Chance (2015)
Palliative thoracic radiotherapy for lung cancer: a systematic review.
A. Fairchild (2008)
Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group.
A. Aupérin (1999)
Thymoma and thymic carcinomas.
M. Scorsetti (2016)
Induction chemotherapy, extrapleural pneumonectomy (EPP) and adjuvant hemi-thoracic radiation in malignant pleural mesothelioma (MPM): Feasibility and results.
F. Rea (2007)
Variations in target volume definition for postoperative radiotherapy in stage III non-small-cell lung cancer: analysis of an international contouring study.
F. Spoelstra (2010)
Novel Predictors of Esophageal Toxicity With Stereotactic Body Radiation Therapy (SBRT) for Central Lung Tumors
K. Stang (2015)
A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer: NRG Oncology RTOG 0915 (NCCTG N0927).
G. Videtic (2015)
Prospective Phase 2 Clinical Trial of Radiation Dose-Escalated Stereotactic Body Radiation Therapy (SBRT) for Centrally Located Lung Cancer: An Institutional Trial
J. Bradley (2015)
Palliative thoracic radiotherapy in non-small cell lung cancer. An analysis of 1250 patients. Palliation of symptoms, tolerance and toxicity.
M. Reinfuss (2011)
Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy.
P. Baumann (2009)
Long-term results of high-dose conformal radiotherapy for patients with medically inoperable T1-3N0 non-small-cell lung cancer: is low incidence of regional failure due to incidental nodal irradiation?
M. Chen (2006)
Pulmonary resection after high-dose and low-dose chest irradiation.
R. Cerfolio (2005)
The Superior Vena Cava Syndrome: Clinical Characteristics and Evolving Etiology
T. Rice (2006)
Steroids, radiotherapy, chemotherapy and stents for superior vena caval obstruction in carcinoma of the bronchus.
N. P. Rowell (2001)
High-dose, conventionally fractionated thoracic reirradiation for lung tumors.
G. Griffioen (2014)
New WHO histologic classification predicts prognosis of thymic epithelial tumors
G. Chen (2002)
Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer.
R. Timmerman (2006)
Consensus statement on palliative lung radiotherapy: third international consensus workshop on palliative radiotherapy and symptom control.
G. Rodrigues (2012)
Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410.
W. Curran (2011)
Prognostic factors and long-term results after thymoma resection: a series of 307 patients.
J. Régnard (1996)
Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group.
R. Ginsberg (1995)
The effect of radiation dose and chemotherapy on overall survival in 237 patients with Stage III non-small-cell lung cancer.
L. Wang (2009)
Survival outcome after stereotactic body radiation therapy and surgery for stage I non-small cell lung cancer: a meta-analysis.
X. Zheng (2014)
Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma.
J. Bradley (2005)
NRG Oncology/RTOG 0937: Randomized Phase 2 Study Comparing Prophylactic Cranial Irradiation (PCI) Alone to PCI and Consolidative Extracranial Irradiation for Extensive Disease Small Cell Lung Cancer (ED-SCLC)
E. Gore (2016)
Chest wall volume receiving >30 Gy predicts risk of severe pain and/or rib fracture after lung stereotactic body radiotherapy.
N. Dunlap (2010)
A meta-analysis of thoracic radiotherapy for small-cell lung cancer.
J. Pignon (1992)
Prevention of tumour seeding following thoracoscopy in mesothelioma by prophylactic radiotherapy.
E. Low (1995)
Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial.
R. Dillman (1996)
The role of radiotherapy in treatment of stage I non-small cell lung cancer.
X. Qiao (2003)
The role of postoperative radiotherapy for stage I/II/III thymic tumor-results of the ChART retrospective database.
Q. Liu (2016)
Computed tomography-guided frameless stereotactic radiotherapy for stage I non-small cell lung cancer: a 5-year experience.
M. Uematsu (2001)
Determinants of Survival in Malignant Pleural Mesothelioma: A Surveillance, Epidemiology, and End Results (SEER) Study of 14,228 Patients
E. Taioli (2015)
Randomized phase III trial of single versus fractionated thoracic radiation in the palliation of patients with lung cancer (NCIC CTG SC.15).
A. Bezjak (2002)
Radiotherapy for locoregional recurrent tumors after resection of non-small cell lung cancer.
Y. Kagami (1998)
Prognostic factors and outcome of incompletely resected invasive thymoma following radiation therapy.
I. Ciernik (1994)
Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma.
M. D. de Perrot (2009)
Relationship Between Radiation Therapy Dose and Outcome in Patients Treated With Neoadjuvant Chemoradiation Therapy and Surgery for Stage IIIA Non-Small Cell Lung Cancer: A Population-Based, Comparative Effectiveness Analysis.
D. Sher (2015)
Radiotherapy alone for medically inoperable stage I non-small-cell lung cancer: the Duke experience.
G. Sibley (1998)
Protocol for PIT: a phase III trial of prophylactic irradiation of tracts in patients with malignant pleural mesothelioma following invasive chest wall intervention
N. Bayman (2016)
The state of the art in the technical performance of lung-sparing operations for malignant pleural mesothelioma.
J. Friedberg (2013)
Postoperative radiotherapy for stage I thymoma: a prospective randomized trial in 29 cases.
H. Zhang (1999)
Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung carcinomas: long-term results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160).
V. Rusch (2007)
Video-assisted thoracoscopic lobectomy versus stereotactic radiotherapy for stage I lung cancer.
M. Hamaji (2015)
Phase II trial of postoperative adjuvant paclitaxel/carboplatin and thoracic radiotherapy in resected stage II and IIIA non-small-cell lung cancer: promising long-term results of the Radiation Therapy Oncology Group--RTOG 9705.
J. Bradley (2005)
Thymoma: Histologic subclassification is an independent prognostic factor
L. Quintanilla-Martinez (1994)
Brachytherapy in the treatment of lung cancer – a valuable solution
J. Skowronek (2015)
Using fluorodeoxyglucose positron emission tomography to assess tumor volume during radiotherapy for non-small-cell lung cancer and its potential impact on adaptive dose escalation and normal tissue sparing.
M. Feng (2009)
Two commonly used neoadjuvant chemoradiotherapy regimens for locally advanced stage III non-small cell lung carcinoma: long-term results and associations with pathologic response.
M. Machtay (2004)
A Comparison of Two Stereotactic Body Radiation Fractionation Schedules for Medically Inoperable Stage I Non-small Cell Lung Cancer: The Cleveland Clinic Experience
K. Stephans (2009)
Diagnosis and treatment of malignant pleural mesothelioma.
F. Rodríguez-Panadero (2015)
Maintenance chemotherapy in small-cell lung cancer: long-term results of a randomized trial. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.
G. Giaccone (1993)
Role of salvage stereotactic body radiation therapy in post-surgical loco-regional recurrence in a selected population of non-small cell lung cancer patients.
L. Agolli (2015)
Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial
M. Pless (2015)
Protocol for the CONVERT trial—Concurrent ONce-daily VErsus twice-daily RadioTherapy: an international 2-arm randomised controlled trial of concurrent chemoradiotherapy comparing twice-daily and once-daily radiotherapy schedules in patients with limited stage small cell lung cancer (LS-SCLC) and goo
C. Faivre-Finn (2016)
Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer.
A. Aupérin (2010)
A study of postoperative radiotherapy in patients with non-small-cell lung cancer: a randomized trial.
Q. Feng (2000)
Guidelines for the diagnosis and treatment of malignant pleural mesothelioma.
N. van Zandwijk (2013)
Prophylactic cranial irradiation (PCI) has a detrimental effect on the overall survival (OS) of patients (pts) with extensive disease small cell lung cancer (ED-SCLC): Results of a Japanese randomized phase III trial.
T. Seto (2014)
Analysis of the Effect of Radiotherapy on Malignant Pleural Mesothelioma when Given on Adjuvant or Palliative Basis
H. E. Hossieny (2010)
Results of the Dutch National study of the palliative effect of irradiation using two different treatment schemes for non-small-cell lung cancer.
G. Kramer (2005)
Standard Terms, Definitions, and Policies for Minimally Invasive Resection of Thymoma
A. Toker (2011)
ACR appropriateness criteria nonsurgical treatment for non-small-cell lung cancer: poor performance status or palliative intent.
K. Rosenzweig (2013)
Esophageal dose tolerance to hypofractionated stereotactic body radiation therapy: risk factors for late toxicity.
K. Stephans (2014)
Superior Vena Cava Syndrome—A Proposed Classification System and Algorithm for Management
J. Yu (2008)
Recommendations for Uniform Definitions of Surgical Techniques for Malignant Pleural Mesothelioma: A Consensus Report of the International Association for the Study of Lung Cancer International Staging Committee and the International Mesothelioma Interest Group
D. Rice (2011)
Postoperative radiation therapy in lung caner: a controlled trial after resection of curative design.
P. van Houtte (1980)
Technical advances of radiation therapy for thymic malignancies.
D. Gomez (2010)
Malignant thymoma in the United States: Demographic patterns in incidence and associations with subsequent malignancies
E. Engels (2003)
Therapy for thymic epithelial tumors: a clinical study of 1,320 patients from Japan.
K. Kondo (2003)
International practice survey on palliative lung radiotherapy: third international consensus workshop on palliative radiotherapy and symptom control.
G. Rodrigues (2012)
Final Results of Phase III Trial in Regionally Advanced Unresectable Non-Small Cell Lung Cancer : Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group
W. Sause (2000)
Radiation Therapy Definitions and Reporting Guidelines for Thymic Malignancies
D. Gomez (2011)
Clinical and dosimetric predictors of radiation pneumonitis in a large series of patients treated with stereotactic body radiation therapy to the lung.
Ryan A. Baker (2013)
Frequency of Use and Predictors of Cancer-Directed Surgery in the Management of Malignant Pleural Mesothelioma in a Community-Based (Surveillance, Epidemiology, and End Results [SEER]) Population
R. Flores (2010)
Stereotactic body radiation therapy for early stage non-small cell lung cancer: results of a prospective trial.
U. Ricardi (2010)
Radiation therapy of stage I and II non-small cell lung cancer (NSCLC).
D. Zierhut (2001)
The role of consolidation therapy for stage III non-small cell lung cancer with persistent N2 disease after induction chemotherapy.
A. Amini (2012)
Outcomes of Stereotactic Ablative Radiotherapy for Centrally Located Early-Stage Lung Cancer
C. Haasbeek (2011)
Women with malignant pleural mesothelioma have a threefold better survival rate than men.
E. Taioli (2014)
Hypofractionated Stereotactic Radiotherapy (HypoFXSRT) for Stage I Non-small Cell Lung Cancer: Updated Results of 257 Patients in a Japanese Multi-institutional Study
H. Onishi (2007)
Results of Proton Beam Therapy without Concurrent Chemotherapy for Patients with Unresectable Stage III Non-small Cell Lung Cancer
Y. Oshiro (2012)
Radiotherapy for the treatment of pain in malignant pleural mesothelioma: a systematic review.
N. Macleod (2014)
High resolution spiral CT for determining the malignant potential of solitary pulmonary nodules: refining and testing the test
S. Harders (2011)
Long-term Results of RTOG 0236: A Phase II Trial of Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Patients with Medically Inoperable Stage I Non-Small Cell Lung Cancer
R. Timmerman (2014)
Need for a new trial to evaluate adjuvant postoperative radiotherapy in non-small-cell lung cancer patients with N2 mediastinal involvement.
C. le Péchoux (2007)
Prophylactic cranial irradiation in extensive small-cell lung cancer.
B. Slotman (2007)
Epidemiology of Thymoma and Associated Malignancies
E. Engels (2010)
A review of 79 thymomas: Modification of staging system and reappraisal of conventional division into invasive and non‐invasive thymoma
K. Koga (1994)
Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide.
A. Turrisi (1999)
Effect of increasing experience on dosimetric and clinical outcomes in the management of malignant pleural mesothelioma with intensity-modulated radiation therapy.
P. Patel (2012)
High-dose conventional thoracic re-irradiation for lung cancer: updated results.
S. Tetar (2015)
Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame.
Y. Nagata (2005)
Primary analysis of the phase II component of a phase I/II dose intensification study using three-dimensional conformal radiation therapy and concurrent chemotherapy for patients with inoperable non-small-cell lung cancer: RTOG 0117.
J. Bradley (2010)
Brachial plexopathy from stereotactic body radiotherapy in early-stage NSCLC: dose-limiting toxicity in apical tumor sites.
Jeffrey A. Forquer (2009)
Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials.
J. Chang (2015)
Pathologic response rates following definitive dose image-guided chemoradiotherapy and resection for locally advanced non-small cell lung cancer.
D. Shumway (2011)
Stereotactic Body Radiation Therapy (SBRT) for lung cancer patients previously treated with conventional radiotherapy: a review
A. Amini (2014)
A prospective phase 2 study of surgery followed by chemotherapy and radiation for superior sulcus tumors
D. Gomez (2012)
Risk of hippocampal metastases in small cell lung cancer patients at presentation and after cranial irradiation: a safety profile study for hippocampal sparing during prophylactic or therapeutic cranial irradiation.
V. Kundapur (2015)
Radical Radiation Therapy After Lung-Sparing Surgery for Malignant Pleural Mesothelioma: Survival, Pattern of Failure, and Prognostic Factors.
E. Minatel (2015)
Final results of the randomized phase III CHARTWEL-trial (ARO 97-1) comparing hyperfractionated-accelerated versus conventionally fractionated radiotherapy in non-small cell lung cancer (NSCLC).
M. Baumann (2011)
THE SUPERIOR VENA CAVA SYNDROME
M. Schechter (1954)
Which patients with extensive stage small-cell lung cancer should and should not receive thoracic radiotherapy?
B. Slotman (2015)
Stereotactic body radiation therapy in centrally and superiorly located stage I or isolated recurrent non-small-cell lung cancer.
J. Chang (2008)
Radiotherapy for Thymic Carcinoma: Adjuvant, Inductive, and Definitive
R. Komaki (2014)
Radiation therapy in the management of medically inoperable carcinoma of the lung: results and implications for future treatment strategies.
D. Dosoretz (1992)
Long-term results in malignant pleural mesothelioma treated with neoadjuvant chemotherapy, extrapleural pneumonectomy and intensity-modulated radiotherapy
C. Thieke (2015)
Preoperative radiotherapy and surgery for advanced thymoma with invasion to the great vessels
E. Akaogi (1996)
Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805.
K. Albain (1995)
Evaluation of individuals with pulmonary nodules: when is it lung cancer? Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.
M. Gould (2013)
Radiotherapy in the treatment of malignant mesothelioma of the pleura, with special reference to its use in palliation.
S. Davis (1994)
Postoperative Radiation Therapy Is Associated With Improved Overall Survival in Incompletely Resected Stage II and III Non-Small-Cell Lung Cancer.
E. Wang (2015)
Pulmonary resection after curative intent radiotherapy (>59 Gy) and concurrent chemotherapy in non-small-cell lung cancer.
J. Sonett (2004)
Intraoperative 125I brachytherapy for high-risk stage I non-small cell lung carcinoma.
A. Chen (1999)
Long-term outcomes after proton therapy, with concurrent chemotherapy, for stage II-III inoperable non-small cell lung cancer.
Q. Nguyen (2015)
Role of radiation therapy in the combined-modality treatment of patients with extensive disease small-cell lung cancer: A randomized study.
B. Jeremic (1999)
Effect of prophylactic cranial irradiation on survival in elderly patients with limited‐stage small cell lung cancer
B. Eaton (2013)
Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer.
W. Sause (1995)
Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma.
M. D. de Perrot (2016)
Postoperative radiotherapy in thymic carcinoma: treatment results and prognostic factors.
H. C. Hsu (2002)
Randomized Trials of Systemic Medically-treated Malignant Mesothelioma: A Systematic Review.
C. Blomberg (2015)
Prognostic factors in the treatment of node-negative nonsmall cell lung carcinoma with radiotherapy alone.
P. Kupelian (1996)
Does myasthenia gravis influence overall survival and cumulative incidence of recurrence in thymoma patients? A Retrospective clinicopathological multicentre analysis on 797 patients.
P. Filosso (2015)
Malignant pleural mesothelioma: an update on biomarkers and treatment.
M. Ray (2009)
Radiotherapy in malignant pleural mesothelioma.
M. McAleer (2009)
Selective nodal irradiation on basis of (18)FDG-PET scans in limited-disease small-cell lung cancer: a prospective study.
J. van Loon (2010)
Stereotactic Body Radiation Therapy for Unbiopsied Early-stage Lung Cancer: A Multi-Institutional Analysis
M. Harkenrider (2014)
Multimodality treatment of thymoma: a prospective study.
F. Venuta (1997)
Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): a randomised clinical trial.
C. le Péchoux (2009)
Use of simultaneous radiation boost achieves high control rates in patients with non-small-cell lung cancer who are not candidates for surgery or conventional chemoradiation.
C. Swanick (2015)
Accelerated hypofractionated radiation therapy compared to conventionally fractionated radiation therapy for the treatment of inoperable non-small cell lung cancer
A. Amini (2012)
Trimodality Treatment of Malignant Pleural Mesothelioma
H. Batırel (2008)
Mature follow-up for high-risk stage I non-small-cell lung carcinoma treated with sublobar resection and intraoperative iodine-125 brachytherapy.
A. Colonias (2011)
External beam radiation therapy alone for loco-regional recurrence of non-small-cell lung cancer after complete resection.
B. Jeremic (1999)
Outcome for Patients with Malignant Pleural Mesothelioma Referred for Trimodality Therapy in Western Australia
A. Hasani (2009)
Time trend of mesothelioma incidence in the United States and projection of future cases: An update based on SEER data for 1973 through 2005
B. Price (2009)
Prospective study of proton beam radiation therapy for adjuvant and definitive treatment of thymoma and thymic carcinoma: Early response and toxicity assessment.
J. Vogel (2016)
Dose escalation study of proton beam therapy with concurrent chemotherapy for stage III non‐small cell lung cancer
H. Harada (2016)
Increasing radiation therapy dose is associated with improved survival in patients undergoing stereotactic body radiation therapy for stage I non-small-cell lung cancer.
M. Koshy (2015)
Prospective, risk-adapted strategy of stereotactic body radiotherapy for early-stage non-small-cell lung cancer: results of a Phase II trial.
S. Bral (2011)
Impact of postoperative radiation therapy on survival in patients with complete resection and stage I, II, or IIIA non-small-cell lung cancer treated with adjuvant chemotherapy: the adjuvant Navelbine International Trialist Association (ANITA) Randomized Trial.
J. Douillard (2008)
A pilot study of [18F]fluorodeoxyglucose positron emission tomography scans during and after radiation-based therapy in patients with non small-cell lung cancer.
F. Kong (2007)
Pulmonary resection after concurrent chemotherapy and high dose (60Gy) radiation for non-small cell lung cancer is safe and may provide increased survival.
R. Cerfolio (2009)
A phase III study of radiotherapy with and without continuous-infusion fluorouracil as palliation for non-small-cell lung cancer.
D. Ball (1997)
Diagnóstico y tratamiento del mesotelioma pleural maligno
Francisco Rodríguez Panadero (2015)
Promising Early Local Control of Malignant Pleural Mesothelioma Following Postoperative Intensity Modulated Radiotherapy (IMRT) to the Chest
A. Ahamad (2003)
Patterns-of-Care for Thoracic Stereotactic Body Radiotherapy among Practicing Radiation Oncologists in the United States
M. Daly (2013)
Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
J. Bradley (2015)
Palliative effectiveness of radiation therapy in the treatment of superior vena cava syndrome.
A. Egelmeers (1996)
Dose--volume metrics associated with radiation pneumonitis after stereotactic body radiation therapy for lung cancer.
Y. Matsuo (2012)
Palliative thoracic radiotherapy in lung cancer: An American Society for Radiation Oncology evidence-based clinical practice guideline
G. Rodrigues (2011)
A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer.
D. Mavroudis (2001)
Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. CHART Steering committee.
M. Saunders (1999)
Comparison between sublobar resection and 125Iodine brachytherapy after sublobar resection in high-risk patients with Stage I non-small-cell lung cancer.
R. Santos (2003)
Postoperative radiotherapy in nonsmall-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials
S. Burdett (1998)
Omitting elective nodal irradiation and irradiating postinduction versus preinduction chemotherapy tumor extent for limited‐stage small cell lung cancer
X. Hu (2012)
5-year prospective results of trimodality treatment for malignant pleural mesothelioma.
V. Pagan (2006)
Final toxicity results of a radiation-dose escalation study in patients with non-small-cell lung cancer (NSCLC): predictors for radiation pneumonitis and fibrosis.
F. Kong (2006)
Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer.
D. Ihde (1994)
Conditional Survival of Malignant Thymoma Using National Population-Based Surveillance, Epidemiology, and End Results (SEER) Registry (1973–2011)
E. Kim (2015)
Thymoma and the increased risk of developing extrathymic malignancies: a multicentre study.
P. Filosso (2013)
Chemotherapy and targeted therapies for unresectable malignant mesothelioma.
R. Kelly (2011)
Malignant pleural mesothelioma.
Sheree E Chen (2012)
Meta-analysis comparing higher and lower dose radiotherapy for palliation in locally advanced lung cancer
Jie-tao Ma (2014)
When is a biopsy-proven diagnosis necessary before stereotactic ablative radiotherapy for lung cancer?: A decision analysis.
A. Louie (2014)
Stereotactic hypofractionated high‐dose irradiation for stage I nonsmall cell lung carcinoma
H. Onishi (2004)
Outcomes of stereotactic ablative radiotherapy following a clinical diagnosis of stage I NSCLC: comparison with a contemporaneous cohort with pathologically proven disease.
N. Verstegen (2011)
High-dose re-irradiation following radical radiotherapy for non-small-cell lung cancer.
D. de Ruysscher (2014)
Prospective Trial of Stereotactic Body Radiation Therapy for Both Operable and Inoperable T1N0M0 Non-Small Cell Lung Cancer: Japan Clinical Oncology Group Study JCOG0403.
Y. Nagata (2015)
Factors influencing the outcome of radiotherapy in malignant mesothelioma of the pleura--a single-institution experience with 189 patients.
L. de Graaf-Strukowska (1999)
Malignant pleural mesothelioma: the standard of care and challenges for future management.
J. Van Meerbeeck (2011)
Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
J. Vansteenkiste (2013)
Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis.
M. Gould (2001)
Induction Chemotherapy, Extrapleural Pneumonectomy, and Postoperative High-Dose Radiotherapy for Locally Advanced Malignant Pleural Mesothelioma: A Phase II Trial
R. Flores (2006)
Review of evolving etiologies, implications and treatment strategies for the superior vena cava syndrome
C. Straka (2016)
Radiation therapy alone for stage I non-small cell lung cancer.
L. Kaskowitz (1993)
Postoperative radiotherapy in radically resected non-small cell lung cancer.
R. Mayer (1997)
Phase II study of accelerated high-dose radiotherapy with concurrent chemotherapy for patients with limited small-cell lung cancer: Radiation Therapy Oncology Group protocol 0239.
R. Komaki (2012)
Radiotherapy for Postoperative Thoracic Lymph Node Recurrence of Non–Small-Cell Lung Cancer Provides Better Outcomes If the Disease Is Asymptomatic and a Single-Station Involvement
J. Okami (2013)
Incidence of local recurrence and second primary tumors in resected stage I lung cancer.
N. Martini (1995)
A controlled study of postoperative radiotherapy for patients with completely resected nonsmall cell lung carcinoma
B. Dautzenberg (1999)
Thoracic Radiotherapy for Extensive Stage Small-Cell Lung Cancer: A Meta-Analysis.
D. Palma (2016)
Patterns of Failure, Toxicity, and Survival after Extrapleural Pneumonectomy and Hemithoracic Intensity-Modulated Radiation Therapy for Malignant Pleural Mesothelioma
D. Gomez (2013)
Re-evaluation of the Role of Postoperative Radiotherapy and the Impact of Radiation Dose for Non–Small-Cell Lung Cancer Using the National Cancer Database
C. Corso (2015)
Reduced lung-cancer mortality with low-dose computed tomographic screening.
D. Aberle (2011)
Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I non-small cell lung cancer.
F. Lagerwaard (2012)
Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019.
K. Albain (2002)
Prophylactic cranial irradiation in extensive disease small-cell lung cancer: short-term health-related quality of life and patient reported symptoms: results of an international Phase III randomized controlled trial by the EORTC Radiation Oncology and Lung Cancer Groups.
B. Slotman (2009)
Role of adjuvant radiotherapy for stage II thymoma after complete tumor resection.
Y. Chen (2010)
The Effectiveness of Postoperative Radiotherapy in Patients With Completely Resected Thymoma: A Meta-Analysis.
D. Zhou (2016)
Salvage stereotactic ablative irradiation for isolated postsurgical local recurrence of lung cancer.
A. Takeda (2013)
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial
G. Zalcman (2016)
Concurrent paclitaxel-based chemo-radiotherapy for post-surgical microscopic residual tumor at the bronchial margin (R1 resection) in non-small-cell lung cancer
M. Zhou (2015)
Treatment of malignant superior vena cava obstruction: metal stents or radiation therapy.
A. A. Nicholson (1997)
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial
B. Slotman (2015)
Primary Study Endpoint Analysis for NRG Oncology/RTOG 0813 Trial of Stereotactic Body Radiation Therapy (SBRT) for Centrally Located Non-Small Cell Lung Cancer (NSCLC)
A. Bezjak (2016)
The probability of malignancy in solitary pulmonary nodules. Application to small radiologically indeterminate nodules.
S. Swensen (1997)
The Masaoka-Koga Stage Classification for Thymic Malignancies: Clarification and Definition of Terms
F. Detterbeck (2011)
Pleural intensity-modulated radiotherapy for malignant pleural mesothelioma.
K. Rosenzweig (2012)
Comparison of treatment outcomes between involved-field and elective nodal irradiation in limited-stage small cell lung cancer.
Tae Jin Han (2012)
A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer.
R. Dillman (1990)
Malignant pleural mesothelioma: an update on diagnosis and treatment options
Sanjana Kondola (2016)
Life-threatening Cerebral Edema Caused by Acute Occlusion of a Superior Vena Cava Stent
K. Sofue (2012)
Treatment and prognosis of primary thymic carcinoma
T. Yano (1993)
A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma.
V. Rusch (2001)
A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma.
C. Cao (2014)
Non-small cell lung cancer: radiation therapy for locoregional recurrence after complete resection
T. Tada (2005)
Stereotactic body radiation therapy for inoperable early stage lung cancer.
R. Timmerman (2010)
Survival after trimodality therapy for malignant pleural mesothelioma: Radical Pleurectomy, chemotherapy with Cisplatin/Pemetrexed and radiotherapy.
S. Boeluekbas (2011)
Stereotactic body radiotherapy (SBRT) for solitary pulmonary nodules clinically diagnosed as lung cancer with no pathological confirmation: comparison with non-small-cell lung cancer.
A. Takeda (2012)
Treatment and prognosis of thymic carcinoma
K. Ogawa (2002)
Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial
K. Albain (2009)
Penetration of recommended procedures for lung cancer staging and management in the United States over 10 years: a quality research in radiation oncology survey.
R. Komaki (2013)
Symptom control and quality of life in people with lung cancer: a randomised trial of two palliative radiotherapy fractionation schedules.
S. Erridge (2005)
Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105.
M. Socinski (2008)
Superior Vena Cava Syndrome with Malignant Causes
L. Wilson (2007)
RTOG 0618: Stereotactic body radiation therapy (SBRT) to treat operable early-stage lung cancer patients.
R. Timmerman (2013)
Association between thymoma and second neoplasms.
J. Welsh (2000)
Double-flash, large-fraction radiation therapy as palliative treatment of malignant superior vena cava syndrome in the elderly
F. Lonardi (2001)
Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B.
J. Herndon (1998)
Toxicity after central versus peripheral lung stereotactic body radiation therapy: a propensity score matched-pair analysis.
V. Mangona (2015)
Sublobar resection with brachytherapy versus lobectomy for stage Ib nonsmall cell lung cancer.
T. Birdas (2006)
Treatment of intervention sites of malignant pleural mesothelioma with radiotherapy: a Dutch-Belgian survey.
D. D. De Ruysscher (2003)
Advanced stage thymomas and thymic carcinomas: results of multimodality treatments.
M. Lucchi (2005)
Phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy, and consolidation chemotherapy for unresectable malignant thymomas: final report.
E. Kim (2004)
Superior Vena Cava Syndrome: A Contemporary Review of a Historic Disease
S. Cheng (2009)
Induction cisplatin/vinblastine and irradiation vs. irradiation in unresectable squamous cell lung cancer: failure patterns by cell type in RTOG 88-08/ECOG 4588. Radiation Therapy Oncology Group. Eastern Cooperative Oncology Group.
R. Komaki (1997)
A Phase 2 Trial of Concurrent Chemotherapy and Proton Therapy for Stage III Non-Small Cell Lung Cancer: Results and Reflections Following Early Closure of a Single-Institution Study.
B. Hoppe (2016)
Outcomes after stereotactic lung radiotherapy or wedge resection for stage I non-small-cell lung cancer.
I. Grills (2010)
Phase 1 study of dose escalation in hypofractionated proton beam therapy for non-small cell lung cancer.
D. Gomez (2013)
Accuracy of FDG-PET to diagnose lung cancer in a region of endemic granulomatous disease.
S. Deppen (2011)
CONVERT: An international randomised trial of concurrent chemo-radiotherapy (cCTRT) comparing twice-daily (BD) and once-daily (OD) radiotherapy schedules in patients with limited stage small cell lung cancer (LS-SCLC) and good performance status (PS).
C. Faivre-Finn (2016)
Is postoperative radiotherapy for thymoma effective?
M. Haniuda (1996)
A randomised controlled trial of intervention site radiotherapy in malignant pleural mesothelioma.
N. O’Rourke (2007)
Therapeutic strategy for postoperative recurrence in patients with non-small cell lung cancer.
T. Yano (2014)
70 Gy thoracic radiotherapy is feasible concurrent with chemotherapy for limited-stage small-cell lung cancer: analysis of Cancer and Leukemia Group B study 39808.
J. Bogart (2004)
Positron emission tomography in limited-stage small-cell lung cancer: a prospective study.
J. Bradley (2004)
The single institutional outcome of postoperative radiotherapy and concurrent chemoradiotherapy in resected non-small cell lung cancer
H. C. Lee (2014)
Proton therapy with concurrent chemotherapy for non-small-cell lung cancer: technique and early results.
B. Hoppe (2012)
Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study.
A. Fakiris (2009)
Role of irradiation in the management of superior vena cava syndrome.
B. Armstrong (1987)
Advances in the diagnosis, treatment and prognosis of malignant pleural mesothelioma.
Weiquan Zhang (2015)
Patterns of tumor recurrence after definitive irradiation for inoperable non-oat cell carcinoma of the lung.
C. Perez (1980)
Treatment and survival analyses of completely resected thymic carcinoma patients
Y. Mao (2015)
The role of palliative radiotherapy in malignant mesothelioma.
D. Bissett (1991)
Effects of postoperative mediastinal radiation on completely resected stage II and stage III epidermoid cancer of the lung. LCSG 773.
T. Weisenburger (1994)
Improved Survival Associated with Neoadjuvant Chemoradiation in Patients with Clinical Stage IIIA(N2) Non–Small-Cell Lung Cancer
M. Koshy (2013)
A dose-volume analysis of radiation pneumonitis in non-small cell lung cancer patients treated with stereotactic body radiation therapy.
R. Barriger (2012)
Salvage stereotactic body radiation therapy (SBRT) for local failure after primary lung SBRT.
J. Hearn (2014)
Invasive thymoma: the role of mediastinal irradiation following complete or incomplete surgical resection.
W. Curran (1988)
Extrapleural pneumonectomy for early stage malignant pleural mesothelioma: a harmful procedure.
O. Rena (2012)
Is surgery still the optimal treatment for stage I non-small cell lung cancer?
D. Moghanaki (2016)
Hemithoracic radiation after extrapleural pneumonectomy for malignant pleural mesothelioma.
S. Yajnik (2003)
The role of post-operative radiotherapy in non-small-cell lung cancer: a multicentre randomised trial in patients with pathologically staged T1-2, N1-2, M0 disease. Medical Research Council Lung Cancer Working Party.
R. Stephens (1996)
Intensity-Modulated Radiotherapy After Extrapleural Pneumonectomy in the Combined-Modality Treatment of Malignant Pleural Mesothelioma
A. Chi (2011)
Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma.
L. Krug (2009)
Follow‐up study of thymomas with special reference to their clinical stages
A. Masaoka (1981)
Omitting elective nodal irradiation during thoracic irradiation in limited-stage small cell lung cancer--evidence from a phase II trial.
R. Colaco (2012)
Adjuvant radiotherapy after extrapleural pneumonectomy for mesothelioma. Prospective analysis of a multi-institutional series.
S. Tonoli (2011)
Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy.
C. Boutin (1995)
Chemotherapy with or without radiation therapy in limited small-cell carcinoma of the lung.
M. C. Perry (1987)
Omission of elective node irradiation on basis of CT-scans in patients with limited disease small cell lung cancer: a phase II trial.
D. D. De Ruysscher (2006)
Impact of brachytherapy on local recurrence rates after sublobar resection: results from ACOSOG Z4032 (Alliance), a phase III randomized trial for high-risk operable non-small-cell lung cancer.
H. Fernando (2014)
This paper is referenced by
Squamous cell carcinoma of lung associated with rare cutaneousparaneoplastic syndrome-systemic lupus erythromatosus (SLE)
R. Siddanna (2017)